Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 7/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 7/20 | 0.34 |
| ▸ | KAT2A | Q92830 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25966746 | 0.78 | HTR2C (0.35) | KAT2BNPC1L3MBTL1IDO1MAOB | |
| SCHEMBL21297851 | 0.76 | L3MBTL1 (0.42) | KAT2BNPC1HSP90AA1L3MBTL1IDO1 | |
| SCHEMBL12439934 | 0.74 | L3MBTL1 (0.36) | KAT2BNPC1HSP90AA1L3MBTL1MAOB | |
| Ammonia Solution, Strong SCHEMBL28358675 | 0.74 | L3MBTL1 (0.41) | KAT2BNPC1HSP90AA1L3MBTL1MAOB | |
| SCHEMBL31221234 | 0.72 | BRD4 (0.43) | NPC1HSP90AA1L3MBTL1KDM4EMAPT | |
| SCHEMBL10129331 | 0.72 | ADORA3 (0.43) | ADORA3ADORA1KDM4EMAPT | |
| SCHEMBL23067956 | 0.71 | GRM4 (0.41) | KAT2BADORA3ADORA1NPC1HSP90AA1 | |
| SCHEMBL570108 | 0.69 | KDM4E (0.41) | KAT2BL3MBTL1MAOBKDM4EMAPT | |
| SCHEMBL26129508 | 0.69 | PAK4 (0.39) | ADORA3ADORA1HSP90AA1IDO1MAPT | |
| SCHEMBL10218715 | 0.68 | PIK3CG (0.43) | KAT2BADORA3ADORA1NPC1HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250088-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-08-10 | — | — | US | disclosed |
| US-20230250060-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250060-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | KAT2B 3238/4885ADORA3 2176/4885ADORA1 1295/4885 |
| US-20230250088-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | KAT2B 3185/4885ADORA3 2193/4885ADORA1 1338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.